| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PD-0332991 | CCLE | pan-cancer | AAC | -0.037 | 0.4 |
| mRNA | neopeltolide | CTRPv2 | pan-cancer | AAC | -0.057 | 0.4 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | -0.042 | 0.4 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.039 | 0.4 |
| mRNA | XL-184 | GDSC1000 | pan-cancer | AAC | -0.027 | 0.5 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | -0.042 | 0.5 |
| mRNA | R428 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.5 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.032 | 0.5 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.029 | 0.5 |